| 1. Accepted major perpetrators | 2. Rejected perpetrators | 3. Unclassifiable | 4. Full table |
ginko biloba is a weak inducer of CYP2C19 and CYP3A.
|Weak inducers||aspirin  |
ginko biloba 
|aprepitant  |
ginko biloba 
- Weak inducers: < 2-fold decrease in AUC or < 50% increase in clearance of in vivo CYP probe.
Footnotes and References
|a.||reported at Clinical Trials.gov ( http://clinicaltrials.gov/ct2/show/study/NCT00785486?sect=X701&view=results ).|
|1.||Chen XP, Tan ZR, Huang SL, Huang Z, Ou-Yang DS, Zhou HH. Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clinical Pharmacology & Therapeutics 2003; 73: 264-71.[PubMed]|
|2.||Yin OQP, Tomlinson B, Waye MMY, Chow AHL, Chow MSS. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004; 14: 841-50.[PubMed]|
|3.||Shadle CR, Lee Y, Majumdar AK, Petty KJ, Gargano C, Bradstreet TE, Evans JK, Blu RA. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. Journal of Clinical Pharmacology 2004; 44: 215-23.[PubMed]|
|4.||Dingemanse J, Schaarschmidt D, van Giersbergen PLM. Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clinical Pharmacokinetics 2003; 42: 293-301.[PubMed]|
|5.||Villikka K, Kivisto KT, Neuvonen PJ. The effect of dexamethasone on the pharmacokinetics of triazolam. Pharmacol Toxicol 1998; 83: 135-38.[PubMed]|
|6.||Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR. Effect of Ginkgo biloba extract on lopinavir, midazolarn and fexofenadine pharmacokinetics in healthy subjects. Current Medical Research and Opinion 2008; 24: 591-99.[PubMed]|
|7.||Ochs HR, Greenblatt DJ, Burstein ES. Lack of influence of cigarette smoking on triazolam pharmacokinetics. British Journal of Clinical Pharmacology 1987; 23: 759-63.[PubMed]|
|8.||Ahonen J, Olkkola KT, Neuvonen PJ. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. British Journal of Clinical Pharmacology 1995; 40: 270-72.[PubMed]|
DisclaimerWARNING: While all efforts were put in to maintain the accuracy and currency of the information, it is possible that the knowledge and electronic tools may contain errors and inadequacy. Both Flinder's University and University of New South Wales are not liable to any damages or losses resulted from such circumstances. Clinical discretions are strongly advised at all times.